Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl by Gutierrez-Berzal, Javier et al.
 1 
CHARACTERIZATION OF p87C3G, A NOVEL, TRUNCATED C3G ISOFORM 
THAT IS OVEREXPRESSED IN CHRONIC MYELOID LEUKEMIA AND 
INTERACTS WITH BCR-ABL 
 
 
 
Javier Gutiérrez-Berzal,1 Esther Castellano,1 Susana Martín-Encabo,1 Noelia 
Gutiérrez-Cianca,1 Jesús M. Hernández,2,1 Eugenio Santos,1 and Carmen 
Guerrero1 
 
 
1Centro de Investigación del Cáncer, IBMCC, University of Salamanca-CSIC; and 
2Servicio de Hematología, Hospital Universitario de Salamanca, 37007-Salamanca, 
Spain. 
 
 
 
 
 
 
Correspondence: 
Carmen Guerrero 
Centro de Investigación del Cáncer, IBMCC 
Universidad de Salamanca-CSIC 
Campus Miguel de Unamuno 
37007 Salamanca, Spain 
tel: 34-923-294801 
fax: 34-923-294743 
cguerrero@usal.es 
 
 
 2 
Abstract 
A novel C3G isoform, designated p87C3G, lacking the most amino terminal region 
of the cognate protein has been found to be overexpressed in two CML cell lines, K562 
and Boff 210, both expressing Bcr-Abl p210. p87C3G expression is also highly 
augmented in patients diagnosed with chronic myeloid leukemia (CML) Ph+, in 
comparison with healthy individuals, and returns to basal levels after treatment with 
STI571. p87C3G coimmunoprecipitates with both CrkL and Bcr-Abl in CML cell lines 
and coimmunoprecipitation between p87C3G and Bcr-Abl was also detected in primary 
cells from CML patients. These interactions have been confirmed by in vitro pull down 
experiments. The interaction between p87C3G and Bcr-Abl involves the SH3-binding 
domain of p87C3G and the SH3 domain of Abl and depends mostly on the first 
polyproline region of p87C3G. Furthermore, we also demonstrated that p87C3G is 
phosphorylated in vitro by a Bcr-Abl-dependent mechanism. These results indicate that 
p87C3G overexpression is linked to CML phenotype and that p87C3G may exert 
productive functional interactions with Bcr-Abl signaling components suggesting the 
implication of this C3G isoform in the pathogenesis of chronic myeloid leukemia.  
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Introduction 
C3G is a Crk-binding protein that shows transformation suppressor activity towards 
several oncogenes through a GEF-independent mechanism [1, 2] involving inhibition of 
ERK1/2 phosphorylation and cyclin A expression and resulting in lost of anchorage 
independent growth [1, 2].  
However, C3G also participates in proliferative pathways through the activation of 
Rap1 [3, 4], and has been described as an essential gene in embryonic development [5] 
and integrin-mediated cellular adhesion and migration [5-8].  
Chronic myeloid leukemia (CML) is a clonal disorder of hematopoietic stem cells 
caused by the Philadelphia chromosome (Ph) translocation [9], which results in the 
generation of the Bcr-Abl fusion oncogene [10]. The N-terminal segment of Abl 
includes a SH3 domain which regulates the tyrosine kinase function of Abl. The fusion 
of Abl to Bcr interferes with the SH3 domain regulatory function causing the Bcr-Abl 
kinase to become constitutively active [11].  
C3G gene localizes to 9q34.3 and is telomeric to the c-abl locus (9q34.1), whose 
gene product is also a Crk-binding protein. In cells derived from CML, CrkL is 
constitutively phosphorylated and is one of the main substrates of Bcr-Abl tyrosine 
kinase [12]. In most cell types C3G is constitutively associated to CrkL, but in cells 
expressing Bcr-Abl this association decreases significantly probably due to the fact that 
both proteins bind CrkL in a mutually exclusive manner [6]. C3G is phosphorylated on 
Tyr-504 when coexpressed with Crk [13] and also C3G is phosphorylated upon 
integrin-mediated cell adhesion [6]. Moreover, it has been recently described that the 
Src family tyrosine kinase Hck, which activity is upregulated in Bcr-Abl expressing 
cells [14, 15], phosphorylate C3G in hematopoietic cells, where both proteins play a 
role in apoptosis [16].  
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Here we describe a novel C3G isoform, p87C3G, highly overexpressed in two 
hematopoietic cell lines related to CML, K562 and Boff 210, as well as in primary cells 
from CML patients at the time of diagnosis. p87C3G, lacks the N-terminal region and 
the first stretch of polyprolines of the SH3-binding (SH3-b) domain and is much more 
abundant than the full length p140C3G form in these cells. p87C3G, interacts with both 
CrkL and Bcr-Abl through its SH3-b domain and is phosphorylated in a Bcr-Abl-
dependent manner, possibly involving Hck. These observations raise interesting 
possibilities for the putative participation of p87C3G in the pathogenesis of CML. 
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Materials and methods 
Cell lines and tissue samples 
K562, a human cell line derived from a patient with chronic myelogenous leukemia 
in terminal blast crisis was obtained from the ATCC (CCL 243) and maintained in 
RPMI 1640 (Life Technologies) containing 10% fetal bovine serum (FBS). Boff 210 is 
an interleukine 3- (IL3) independent cell line derived from the hematopoietic cell line 
BaF/3 [17] that expressed Bcr-Abl as a tetracycline-regulated transgene (Bcr-Abl 
expression is constitutive in absence of tetracycline or doxycycline). Boff 210 was 
maintained in DMEM (Life Technologies) supplemented with 10% FBS.  
Mononuclear cells were obtained from blood samples of healthy individuals and 
CML patients in chronic phase (i) before treatment (more than 90% Ph+), (ii) treated 
with STI571 for two weeks (~50% Ph+) or (iii) with complete cytogenetic response 
after 6 months treatment with STI571 (0% Ph+) by lysing the red cells in a buffer 
containing 0.13 mM EDTA, 10 mM HKCO3 and 0.15 M ClNH4. All primary samples 
were provided by Hospital Universitario de Salamanca (Salamanca, Spain). 
 
Agonists 
IFN-α was supplied by Calbiochem (Darmstadt, Germany) and used at 104 U/ml 
for 5 min. EGF was purchased from Becton Dickinson (Franklin Lakes, NJ) and used at 
200 ng/ml for 2 min. 
 
Kinase inhibitors 
STI571 (imatinib mesylate), an inhibitor of the Bcr-Abl kinase activity, was a gift of 
Novartis Pharma Ag, Basel, Switzerland. STI571 was stored in DMSO as a 10 mM 
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stock solution at -20ºC. Cells were treated for 24 h with 1 µM STI571 or with solvent 
only. 
5´ RACE 
5´RACE (rapid amplification of 5´cDNA ends) was performed with a kit by Roche 
Molecular Biochemicals, following manufacturer’s recommendations, using two sets of 
three neighbouring primers: (1) mC3G-N1 
(GGTCACCCTCTGAGATGTTGTCATAC), mC3G-N2 
(ACTGTGAGGGGTGTCGCTCATAGG) and mC3G-N3 
(AAAGGATCCATAGGACACCCTGCAGCCAGAG) corresponding to positions 
1482-1507, 1460-1483 and 1443-1464 respectively of mouse C3G gene (accession 
number: AF348669) and (2) mC3G-C1 (GGTCTTCTCTTCGCGGTCTGTTTTCC), 
mC3G-C2 (CAGAGAGAGTTCCCACAGGGCTTC) and mC3G-C3 
(AAAGGATCCAGAGTTCCCACAGGGCTTCCTC) corresponding to positions 
3233-3258, 3181-3204 and 3178-3199 respectively. mC3G-N3 and mC3G-C3 were 
designed with extra 9 nucleotides including a restriction site for BamHI (in bold). After 
cloning into ClaI-BamHI sites of plasmid pSP72 (Promega), fragments were sequenced 
using primers SP6 (ATTTAGGTGACACTATAGAACTC) and T7 
(TAATACGACTCACTATAGGGAGA) in an automatic sequencer.  
 
Northern blot  
Total RNA from Boff 210 cells (20 µg) was loaded into a formaldehyde agarose gel 
and blotted to a Hybond-N+ membrane (Amersham Biosciences). The blot was 
hybridized with a 0.96 Kb cDNA fragment, containing nucleotides 2272 to 3231 of 
human C3G. The cDNA probe was 32P-labelled by random priming (Stratagene) and 
used under high stringency hybridization conditions at 42oC in the presence of 50% 
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(vol/vol) formamide, 5x SSPE (1x SSPE = 150 mM NaCl, 10 mM sodium phosphate 
pH 7.4, 1 mM EDTA), 100 µg/ml herring testes DNA, 1% SDS, and 5x Denhardt’s 
solution. After 24-36 h of hybridization, the membrane was washed three times in 0.1x 
SSC, 0.1% SDS at 50oC and autorradiographed at -70oC in the presence of intensifying 
screens.   
 
Antibodies and immunological studies 
We have used the following antibodies: anti-C3G (c-19), anti-C3G (H-300), anti-c-
Abl (24-11), anti-Bcr (G6), anti-Rap1 (121), anti-Actin (c-11), anti-tubulin (tu-02), anti-
Crk-L (H-62), anti-Hck (N-30) and anti-phospho-tyrosine (PY20) from Santa Cruz 
Biotechnologies (Santa Cruz, CA) and anti-Hck mAb from BD transduction laboratories 
(Cat. No: 610277). 
Whole cell lysates were prepared by extracting with Cell Lysis Buffer purchased 
from Cell Signaling Technology, Inc. (#9803).  
 
Immunoprecipitations and In vitro phosphorylation 
Immunoprecipitations and in vitro Kinase assays were performed as described [16]. 
For the in vitro kinase assays either, 20 µCi [γ32P] ATP or 10 µM cold ATP were used.  
The samples were resolved by SDS-PAGE and exposed to autoradiography or revealed 
with anti-phospho-tyrosine (p-Tyr) antibodies. 
 
Constructs in pGEX vectors 
A fragment containing part of the catalytic region of human C3G gene was cloned 
into pGEX-4T-3 (Amersham Biosciences) as a SmaI (n2479)-BamHI (n3247) fragment 
obtaining construct pGST-CAT. Full length p87C3G was cloned as a BamHI-EcoRV 
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fragment into BamHI-SmaI of plasmid pGEX-3X (Amersham Biosciences), obtaining 
construct pGST-p87. pGST-P2 contains the second polyproline stretch of C3G as a 
BamHI (n840)-BsrB1 (n1437) fragment cloned into BamHI-SmaI of pGEX-3X. Entire 
C3G SH3-binding domain was cloned by PCR using primers AF45 
(GCTCGGATCCATGAAGCAGGGACGTC) and AF46R 
(CTTCAGATCTTTACGACTGAGCCGACTC), containing respectively BamHI and 
BglII sites (in bold), and introduced into BamHI site of pGEX-3X giving construct 
pGST-SH3-b.  
A fragment of 419 bp containing Abl SH3 domain (nucleotides 2734 to 3152 of the 
p210 Bcr-Abl fusion gene) was cloned using primers p210F2-BamHI 
(CCCGGATCCTTTCTGAATGTCATCGTCC) and p210R2-EcoRI 
(CCCGAATTCAGAAGCTGCCATTGATCC) and introduced into BamHI-EcoRI sites 
of pGEX-4T-1 generating pGST-SH3Abl. 
 
Bacterial expression of GST fusion proteins 
Constructs pGST-CAT, pGST-C3G12 [1], pGST-SH3-b, pGST-p87, pGST-P2 and 
pGST-SH3Abl were expressed in BL21 pLys strain of Escherichia coli and the 
corresponding GST-fusion proteins purified using the glutathione-agarose affinity 
method as described [18]. pGST-RalGDS-RBD (GST fused to the Ras binding domain 
of RalGDS, amino acid residues 701-851), was obtained from Dr. P. Crespo (University 
of Cantabria/Instituto de Investigaciones Biomédicas, Santander, Cantabria, Spain).  
 
Rap1 activity assay 
Boff 210 cells were growth to 1.5 x 105 cells/ml and serum starved for 20-24 h 
followed by incubation with EGF (epidermal growth factor) or IFN-α (interferon-α). 
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After treatment, cells were washed twice with cold PBS and lysed in 500 µl of Mg2+ 
lysis/wash buffer (MLB) containing 25 mM HEPES, pH 7.5; 150 mM NaCl, 1% igepal 
CA-630, 10 mM MgCl2, 1 mM EDTA, 2% glycerol, 1 mM Na3VO4, 25 mM NaF, 1mM 
PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin. Fresh cell lysates were diluted to 
roughly 1 µg/µl total cell protein with MLB and the lysates were precleared with 
glutathione agarose beads. After that, 1 mg of cell lysate was incubated with 10-15 µg 
pGST-RalGDS-RBD glutathione agarose conjugated per assay and the mixture was 
gently rocked at 4oC for 30 min. Agarose beads were collected by pulsing and the 
supernatant was drained off. The beads were washed 3 times with MLB, resuspended in 
appropriate amount of Laemmli sample buffer and boiled for 5 min. Supernatants were 
collected and loaded onto 12% SDS-PAGE. Rap1-GTP was detected with 1µg/ml anti-
Rap1 antibodies.  
 
Pull down experiments 
Pull downs from cell extracts were carried out by incubating 1 mg of protein extract 
in lysis buffer with 0.1 to 2 µg of GST-fusion proteins, bound to glutathione-sepharose 
beads, for 2 hours at 4oC. Complexes were subjected to 3 washes in lysis buffer and 
boiled in loading buffer before SDS- PAGE. 
 
In vitro mutagenesis 
Plasmid pGST-p87, containing whole p87C3G clone, was subjected to in vitro 
mutagenesis by PCR using Pfu TURBO DNA polymerase (Stratagene) and the 
following pairs of oligos: CSH3b2-MutF 
(GCAGACAGATACGGCAGCTGCTCTCGCCGAGAAGAAGCG) and CSH3b2-
MutR (CGCTTCTTCTCGGCGAGAGCAGCTGCCGTATCTGTCTGC); CSH3b3-
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MutF (GACCCAGAAAAACCAGCTGCTCTAGCAGAGAAGAAAAA) and 
CSH3b3-MutR (TTTTTCTTCTCTGCTAGAGCAGCTGGTTTTTCTGGGTC); 
CSH3b4-MutF (GAGCTGGCCCCGGCGGCCGCCCTAGCCCCCAAGCAGCGG) 
and CSH3b4-MutR 
(CCGCTGCTTGGGGGCTAGGGCGGCCGCCGGGGCCAGCTC), where the 
mutated nucleotides are in bold (Proline to Alanine substitutions).  
The PCR reactions were carried on at 95º, 30s; 55º 1 min; 68º, 11 min for 12 cycles and 
the mutations verified by automatic sequencing. 
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Results 
Detection of a novel C3G isoform in K562 and Boff 210 cells 
Type I and type II interferons, often used as a treatment for CML, activate CrkL-
Rap1 signaling pathway in hematopoietic cells, presumably through the activation of 
C3G [19, 20]. To further study the involvement of C3G in this pathway, our first goal 
was to determine the expression of C3G in two models of CML, human K562 cells and 
mouse Boff 210 cells, as well as in primary CML patient samples. Both, K562 cells, 
growing in the presence (C) or absence (st) of 10% fetal bovine serum, and Boff 210 
cells, untreated or treated with doxycycline (20 µg/ml, 48 h) and/or IL3 (10% of a 
conditioned media from WEHI cells), expressed good amounts of p210 Bcr-Abl (Figure 
1A). Immunoblotting of total cell lysates from both K562 (Figure 1B) and Boff 210 
(Figure 1C) cells with anti-C3G (c-19) antibodies detected a putative C3G isoform of 
approximately 87 kDa which is much more abundant than full length, 140 kDa, C3G 
form. Similarly, p87C3G is highly overexpressed in samples from CML patients at time 
of diagnosis as compared to healthy individuals (Figure 1D). This CML-associated 
p87C3G expression returns to basal levels after treatment with STI571 (Figure 1D).  
The authenticity of this band was confirmed by specific blockage with the 
corresponding blocking peptide, which completely competed both p140C3G and 
p87C3G bands (Figure 1B,C right panel, Figure 1D middle panel). Furthermore, the 
p87C3G band is not recognized by an anti-C3G antibody against the 300 first amino 
acids of the protein (C3G H-300), which indicates that p87C3G conserves the C-
terminus of full length C3G but it is truncated at its N-terminus (Figure 1E).  
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Cloning of the 5´end of p87C3G by RACE: estimation of p87C3G start point 
The above results with anti-C3G (H-300) and anti-C3G (c-19) antibodies suggest that 
p87C3G lacks, at least, the first 300 amino acids of the entire C3G protein, while it 
contains an intact C-terminus. To determine the start point of this isoform, we 
performed 5´RACE analysis using total RNA from Boff 210 cells and two sets of three 
adjacent oligonucleotides, mC3G-C1, 2, 3 and mC3G-N1, 2, 3 oligos (Figure 2A). 
We sequenced a total of 23 clones from de N-terminal amplification and 10 clones 
from the C-terminal amplification, which size ranged between 252-494 nucleotides and 
677-1162 nucleotides, respectively.  The longer, most 5´, fragment from the N-terminal 
amplification started at nucleotide 971 of the mouse sequence and the longer fragment 
from the C-terminal amplification started at 2037. Thus, we could not obtain a single 
clone containing the complete p87C3G cDNA, probably due to limitations of the 
technique. There is an ATG site located at position 961, just ten nucleotides upstream 
the beginning of the longer N-terminal RACE clone, which corresponds to amino acid 
321. This Met residue is very likely the start position of p87C3G as discussed below 
(see Discussion Section). In human C3G, the equivalent ATG starts at nucleotide 916 
and corresponds to amino acid 306.  
Additionally, Northern analysis on Boff 210 total RNA revealed two transcripts of 
7.5 and 4.4 kb (Figure 3). The 7.5 kb transcript presumably encodes full-length 140kDa 
C3G protein, as it is ubiquitously detected [1, 21]. The shorter, 4.4 kb transcript has 
been previously described in adult human heart and skeletal muscle where, in 
concordance, a 80-90 kDa transcript was also detected [1]. The presence of two 
transcripts in Boff 210 is in agreement with the detection of the two C3G isoforms 
(p140 and p87) in these cells. 
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All these results suggest that p87C3G isoform is not originated from full length C3G 
by proteolytic digestion but it is translated from a spliced C3G mRNA.  
 
Interaction of p87C3G with CrkL and Bcr-Abl 
Immunoblotting of CrkL immunoprecipitates with anti-C3G (c-19) antibody revealed 
that p87C3G interacts with CrkL in K562 and Boff 210 cells (Figure 4A). Under our 
experimental conditions, we were unable to detect this interaction with full length 
p140C3G. The interaction between p87C3G and CrkL increased in cells treated with 
EGF, a known activator of the CrkL-Rap1 pathway [22] and when the expression of 
Bcr-Abl decreases (Boff 210 cells treated with doxycycline, Figure 1A, lower panel) 
(Figure 4A). In agreement with these results, Rap1 activation by EGF or IFN-α 
increased dramatically in Boff 210 cells previously treated with doxycycline (Figure 4 
B). All these results are in concordance with a previous report suggesting competition 
between Bcr-Abl and C3G in their binding to CrkL [6]. 
Next, we studied whether p87C3G was also able to interact with Bcr-Abl in K562 
and Boff 210 cells. We immunoprecipitated Bcr-Abl with anti-Abl antibodies and 
detected the presence of p87C3G in the Abl immunoprecipitates using anti-C3G 
antibodies (Figure 4C). Same results were obtained with anti-Bcr antibodies (data not 
shown). As expected, interaction between p87C3G and Bcr-Abl in Boff 210 cells 
decreases in the presence of doxycycline (Figure 4C, right panel). Interestingly, we 
could also observe this interaction in mononuclear cells lysate from a primary CML 
sample at the time of diagnosis but not in a healthy individual or a CML patient in 
complete remission after treatment with STI571 (Figure 4D), further confirming its 
relevance in vivo.  
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p87C3G interacts with Bcr-Abl through its SH3-binding domain 
To characterize the p87C3G region involved in the interaction with Bcr-Abl, we 
performed pull down experiments of K562 lysates with several constructs of C3G fused 
to GST (Figure 2B).  Figure 5A shows that only pGST-C3G12 and pGST-p87, 
containing, respectively, most of p87C3G and putative full length p87C3G, were able to 
pull down Bcr-Abl under these conditions, whereas constructs containing only the 
catalytic domain (GST-CAT) or the SH3-binding domain complete or partial (GST-
SH3-b and GST-P2), failed to do so. As expected, constructs containing the SH3-
binding domain complete or partial (but not the catalytic domain) were also able to 
interact with CrkL.  
Bcr-Abl protein contains a SH3 domain that could potentially interact with the SH3-
binding domain of C3G. To test this hypothesis we cloned the SH3 domain of Bcr-Abl 
fused to GST and performed pull down assays in K562 lysates with the resulting 
construct pGST-SH3Abl. Figure 5B shows that the SH3 domain of Bcr-Abl interacts 
with both p87C3G and CrkL. This interaction is specific of the SH3 domain of Bcr-Abl, 
since GST alone did not interact with p87C3G or with CrkL.  
 
Contribution of the P2 region of the C3G SH3-binding domain is essential for its 
interaction with Bcr-Abl  
To further confirm the specificity of the interaction between p87C3G and Bcr-
Abl, we performed in vitro mutagenesis of the C3G SH3-binding domain, using pGST-
p87 construct. We designed three different mutants of the C3G SH3-binding region, 
each one mutated in a different polyproline region (P2, P3 and P4, Figure 2B) with all 
the Prolines substituted by Glycines. Pull down experiments with these mutants (mP2, 
mP3 and mP4) showed that only mutations in the P2 region of the C3G SH3-binding 
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domain significantly decrease the interaction between p87C3G and Bcr-Abl (Figure 
5C), suggesting that this region is the most important in the interaction between 
p87C3G and Bcr-Abl. Mutations in this polyproline stretch did not significantly affect 
to the interaction with CrkL (Figure 5C). 
 
p87C3G is phosphorylated through a Bcr-Abl kinase-dependent mechanism 
C3G is phosphorylated on Tyr-504 upon integrin-mediated cell adhesion [6] or 
coexpression with CrkI [13]. Recently the Src family tyrosine kinase Hck, which is 
specifically activated by Bcr-Abl in hematopoietic cells [14], was described to 
phosphorylate C3G in this cell type, where both proteins play a role in apoptosis [16]. 
Related to this, both CrkL and p87C3G are constitutively tyrosine phosphorylated in 
Boff 210 and K562 cells (Figure 6A). In Boff 210 cells, p87C3G phosphorylation 
increased in the presence of doxycycline suggesting a negative dependence on Bcr-Abl 
in this process. Additionally, IFN-α, an antagonist of Bcr-Abl function slightly 
increased p87C3G tyrosine phosphorylation in K562 cells.  
To further investigate the role of Bcr-Abl on C3G phosphorylation in CML cells we 
performed in vitro kinase assays on K562 cell lysates immunoprecipitated with anti-
Abl, anti-C3G (c-19) or anti-Hck antibodies. The reaction products were detected by 
autoradiography (Figures 6B,C) or with anti-p-Tyr antibodies (Figure 6D). Both 
p140C3G and p87C3G were found phosphorylated in the C3G immunoprecipitates, 
indicating that C3G interacts and is a substrate for cellular kinase activities (Figure 6B). 
Besides, p87C3G was also tyrosine phosphorylated in the Abl immunocomplexes, 
presumably through the kinase activity of Bcr-Abl, as this phosphorylation decreases in 
cells treated with STI571, a known inhibitor of the Bcr-Abl kinase function, (Figure 6C 
and Figure 6D, upper panel). In agreement with previous reports [16], p87C3G was also 
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found tyrosine phosphorylated in Hck immunoprecipitates being this phosphorylation 
also dependent on Bcr-Abl kinase (Figure 6D). The presence and phosphorylation of 
p87C3G and Hck in the immunoprecipitates are specific as these proteins are absent in 
control cell lysate incubated with beads (data not shown). Thus, the phosphorylation of 
p87C3G seems to occur in a complex with Bcr-Abl and Hck and is, at least in part, 
dependent on Bcr-Abl activity.  
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Discussion 
In this paper, we described the detection and characterization of a novel C3G 
isoform, p87C3G, which may play a putative role in the pathogenesis of CML since its 
expression is significantly increased in untreated CML patients, as compared to normal 
healthy donors or patients treated with STI571, and interacts with the Bcr-Abl oncogene 
responsible of the malignant transformation of CML cells. p87C3G is also detected in 
unrelated tissues, like NIH 3T3 fibroblasts, although at very low levels compared to 
CML cell lines (data not shown). In addition to the ubiquitous 7.5 kb transcript, 
corresponding to full length C3G, a second transcript of about 4.4 kb was detected in 
Boff 210 RNA, in agreement with the presence of p87C3G in these cells. A shorter 
transcript of similar size, containing the 3´end of C3G but lacking the 5´end,  was also 
previously described in tissues such as human heart and skeletal muscle where, in 
accordance, a band of 80-90 kDa was also present at the protein level [1]. 
Under our experimental conditions, we have been unable to detect interaction 
between Bcr-Abl and full length C3G, probably due to its low expression in CML cells. 
A recent article by Cho et al, showed p140C3G/Bcr-Abl interaction, although it has to 
be mention that the authors only detected this interaction in COS cells transfected with 
the corresponding DNAs but not in K562 cells of in MEFs from Bcr-Abl p190 
transgenic mice [23]. Also results by these authors suggesting cooperation between 
Rap1 pathway and Bcr-Abl are in disagreement with our results where Rap1 is highly 
activated when Bcr-Abl expression decreases by the presence of doxycycline (Figure 
4B). The antagonism between the CrkL-Rap1 and the Bcr-Abl pathways has been 
reported by other authors demonstrating that, in fact, the CrkL-Rap1 pathway exhibits 
suppressive effects on Bcr-Abl expressing cells [20, 24, 25]. 
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Using rapid amplification of 5´cDNA ends (RACE) technique, we identified the 
putative start codon of p87C3G at positions 321 and 306 of mouse and human C3G 
proteins respectively, located after the first Proline-rich stretch. RACE allowed us to 
generate fragments upon 1 kb in length when using oligonucleotides from the 3´end of 
C3G gene (C-T oligos). The fact that all the N-T fragments obtained were smaller than 
500 bp strongly suggests these fragments nearly reached the 5´ end of the corresponding 
mRNA. Nevertheless, it is surprising that we could not obtain larger fragments with the 
N-T oligonucleotides, considering that both mRNA species (full length p140C3G and 
p87C3G) must coexist in the cell. A plausible explanation is that p87C3G is much more 
abundant and/or more stable than full length C3G in these cells, thus favouring the 
amplification of p87C3G RNA in the RACE reaction. We consider that Met 306 of 
human C3G (321 of mouse protein) is the putative start of p87C3G for the following 
reasons: (i) Previous Met is located at position 250 (human C3G). Considering that 
antibody anti-C3G H-300 does not recognize p87C3G, it is very unlikely this isoform 
contains residues upstream aminoacid 300. In fact, this antibody perfectly recognizes 
the peptide encoded by a fragment containing the C3G SH3-b domain that starts, just 
exactly, at residue 250 (data not shown). (ii) Next Met is located at residue 551. Again, 
this Met can not be the starting of p87C3G since, as shown in Figure 6, this isoform is 
tyrosine phosphorylated and also recognized by an antibody specifically raised against 
the phosphorylated Tyr 504 (data not shown), the only Tyr residue susceptible of 
phosphorylation in C3G [13]. (iii) Finally, mutations in the P2 polyproline stretch (~aa 
440-460) revealed that this segment is involved in p87C3G/Bcr-Abl interaction. 
Fluorescence in situ chromosomal hybridization (FISH) revealed that there is a single 
chromosomal loci for C3G gene at 9q34.3 [26], strongly suggesting that the p87C3G 
isoform arises from alternative splicing of a unique transcript. Besides, Shrivakrupa et 
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al. cloned a C3G fragment (C9) from a rat spleen cDNA library that also started just 
after the first Proline-rich stretch, similarly to our p87C3G clone [27], further 
supporting the idea of p87C3G being an alternative spliced form of C3G. 
Both p87C3G and C3G12 (lacking the first 86 amino acids of p87C3G) interact with 
CrkL and Bcr-Abl. These interactions were specific of the mentioned fragments, as the 
catalytic region alone did not interact either with CrkL (as expected) or with Bcr-Abl. 
Small fragments containing (totally or partially) just the SH3-binding region failed to 
pull down Bcr-Abl, whereas they interacted with CrkL. It is possible that the interaction 
Bcr-Abl/p87C3G involves only the SH3-b domain of p87C3G although the rest of the 
p87C3G protein is necessary for  the stability of the binding. 
In addition, our data indicate that at least the SH3 domain of Abl is involved in the 
interaction between Bcr-Abl and p87C3G. A previous report established that the C3G 
SH3-binding domain only interacts with CrkL and, weakly, with Grb2 N-SH3 domain 
but not with Abl SH3 domain [28], although It should be mentioned that these 
experiments were performed in vitro and in HeLa cells. Surprisingly, the SH3 domain 
of Bcr-Abl also interacts with CrkL. This would constitute an additional interaction site 
between these two molecules, since it is known that Bcr-Abl also interacts with CrkL 
through the SH3-binding domain of Bcr-Abl and the N-T SH3 domain of CrkL [12, 29]. 
There is evidence for a potential SH3-binding domain inside the SH2 domain of CrkL 
that may explain this interaction [30]. 
In vitro mutagenesis experiments demonstrated that the second Proline-rich domain 
(P2) of C3G (i.e. the first polyproline stretch in p87C3G) is the most critical in the 
interaction with Bcr-Abl and confirm the specificity of such interaction as mutations in 
this domain only affect to the interaction of p87C3G with Bcr-Abl but not to the 
interaction with CrkL (Figure 5C).  
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Kinase studies performed in Figure 6 revealed that (i) p87C3G is found tyrosine 
phosphorylated in Boff210 and K562 cells, (ii) C3G proteins coimmunoprecipitate with 
a tyrosine kinase activity, (iii) only p87C3G, but not p140C3G (at least under the 
experimental conditions used) is phosphorylated in vitro in a Bcr-Abl-dependent 
manner, and (iv) p87C3G is also phosphorylated in Hck immunocomplexes by a Bcr-
Abl kinase-dependent mechanism. Thus, the phosphorylation of p87C3G seems to 
occur in a complex with Bcr-Abl and Hck and is dependent, at least partially, on Bcr-
Abl activity since addition of STI571 to the reaction decreases p87C3G 
phosphorylation. We also found Hck to be tyrosine phosphorylated in both C3G and 
Hck immunocomplexes, being this phosphorylation independent on Bcr-Abl catalytic 
activity, in agreement with a previous report [15]. Nevertheless, contrarily to those 
authors, we were unable to detect Hck in Abl immunocomplexes (Figure 6D, lower 
panel). One interesting point is that, although p87C3G phosphorylation seems to be 
mediated by Bcr-Abl catalytic activity, the interaction between Bcr-Abl and p87C3G is 
independent on Bcr-Abl kinase as it does not vary in the presence of  STI571 (Figure 
6D, lower panel). 
On the other hand, data in Figure 6A also indicate that p87C3G is constitutively 
phosphorylated on tyrosine residues in K562 and Boff 210 cells and that decreasing of 
Bcr-Abl expression (treatment with doxycycline in Boff 210 cells and treatment with 
IFN-α in K562 cells) increases p87C3G phosphorylation. These observations are in 
agreement with previous results showing that there is competition between the Bcr-Abl 
oncogene and cellular proteins, such as C3G, for their binding to the adapter proteins 
CrkL and Crk [6, 31] and suggest that C3G is involved in p210 Bcr-Abl signaling. 
Nevertheless, these results are in apparent contradiction with the kinase assay results 
(Figures 6B-D) showing a dependence of p87C3G phosphorylation on Bcr-Abl kinase 
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function. One possible explanation is that several pathways phosphorylating C3G 
coexist in hematopoietic cells. Thus, in Figure 6B-C we are detecting only p87C3G 
directly phosphorylated by kinase activities that form complexes with C3G, presumably 
Bcr-Abl and Hck, while in Figure 6A we are detecting all phosphorylated p87C3G in 
the cell. It is well known that C3G phosphorylation is modulated by cell adhesion and 
that this property is altered in CML cells. In fact, CML cells express an adhesion-
inhibitory variant of β1 integrin that is not found in normal progenitors [10]. In the 
presence of Dx, when Bcr-Abl expression is decreased, there is an increase in p87C3G 
phosphorylation (Figure 6A), probably due to an increase in CrkL available to interact 
with p87C3G (Figure 4A) which results in an increase in Rap1 activation (Figure 4B). 
In hematopoietic cells activation of Rap1 triggers an “inside out” signal that activates 
integrin-mediated cell adhesion [10, 32]. Reciprocally, it also possible that when the 
expression of Bcr-Abl decreases there is an increase in β integrins-mediated cell 
adhesion that can activates the CrkL-C3G-Rap1 pathway through an “outside in” signal 
[6, 8, 10, 32-34]. 
Curiously, the SH3 domain of Bcr-Abl is the one involved in regulation of adhesion 
to laminin and collagens of leukemic cells through the formation of α2β1 integrin 
complexes [35], which is in agreement with a functional cooperation between p87C3G 
and Bcr-Abl by its SH3 domain.  
In conclusion, we have described a novel isoform of C3G (p87C3G) abundantly 
expressed in CML cells that, through its interaction with the SH3 regulatory domain of 
Bcr-Abl, may play a role in the pathogenesis of CML. Further studies will be necessary 
to investigate the significance of this novel connection between Bcr-Abl and p87C3G, 
and whether it is related to the adhesive properties of leukemic cells.  
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Legends to Figures 
Figure 1. Expression of p87C3G in Bcr-Abl-expressing cells. (A) Bcr-Abl 
expression in K562 and Boff 210 cell lines. Lysates were immunoprecipitated with anti-
Abl antibodies and analyzed by immunoblotting with antibodies to Bcr. (B,C) C3G 
expression in K562 and Boff 210 cell lysates (20 µg) using anti-C3G (c-19) antibody 
(left panels, 5 min exposure with ECL). Both p140 and p87 bands were completely 
competed using the corresponding blocking peptide (right panels, 2 h exposure with 
ECL plus). (D) C3G expression in primary mononuclear cells from healthy individuals 
(H) and CML patient samples at different stages of treatment with STI571 (30 µg) using 
anti-C3G (c-19) antibody (upper panel, 2 min exposure with ECL). p140 and p87C3G 
were completely competed with blocking peptide (middle panel, 30 min exposure with 
ECL plus). >90%, CML patient samples containing more than 90% Ph+ cells; 50%, 
CML patients containing about 50% Ph+ cells; 0%, samples from CML patients in total 
remission after treatment with STI571 (0% Ph+ cells). (E) Antibody anti-C3G (H-300) 
does not recognize p87C3G in Boff 210 cell lysates. Actin or tubulin were used as 
control of protein loading. C, exponentially growing cells; st, serum-starved cells; IL3, 
interleukine 3; Dx, doxycycline; BP, blocking peptide. Blots are representative of 2 or 3 
independent experiments. 
 
Figure 2. Strategy of p87C3G cloning and constructs in pGEX vectors. (A) 
Schematic representation of C3G indicating the putative start of p87C3G and the 
position of the sets of oligonucleotides used in 5´RACE analysis. SH3-b, SH3-binding 
region; REM, Ras exchange motif; CDC25-H, catalytic or exchange domain. Regions 
recognized by C3G (c-19) and C3G (H-300) antibodies are indicated. (B) Schematic 
representation of C3G fragments cloned as GST fusion proteins, indicating the names of 
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the resulting constructs. P2, P3 and P4 correspond to the polyproline stretches 2, 3 and 4 
of the SH3-b domain.  Numbers correspond to amino acid positions of human C3G 
protein. 
 
Figure 3. Northern analysis of Boff 210 total RNA. A 0.96 Kb PCR fragment, 
containing nucleotides 2272 to 3231 of human C3G was [32P]α-dCTP labelled and 
hybridized to a Northern blot containing 20µg of total RNA from Boff 210 cells. The 
sizes of the two transcripts detected and the 28S rRNA position are indicated. M, 
molecular weight marker. 
 
Figure 4. p87C3G interacts with CrkL and Bcr-Abl. (A) Lysates (1 mg) of Boff 
210 cells (untreated or treated with 20 µg/ml doxycycline for 48 h) and K562 cells 
(untreated and treated for 2 min with 200 ng/ml EGF) were immunoprecipitated with 
anti-CrkL antibodies and immunoblotted using anti-C3G (c-19) antibodies. 
Immunoblots showing the amount of p87C3G in the lysates are presented in the lower 
panels. (B) Rap1-GTP from Boff 210 cells, treated with EGF or IFN-α in the presence 
or absence of doxycycline, was pull down with purified GST-RalGDS RBD-glutathione 
agarose beads and detected with anti-Rap1 antibodies (upper panel). Total Rap1 was 
detected from the same lysates by Western blot with same antibodies (lower panel).  (C) 
K562 and Boff 210 cell lysates were immunoprecipitated with anti-Abl or anti-C3G (c-
19) antibodies and analyzed by immunoblotting with antibodies to C3G (c-19) or CrkL. 
Immunoblots in lower panels show equal amounts of p87C3G in all lysates. C, 
exponentially growing cells; st, serum-starved cells; Dx, doxycycline. Panels are 
representative of 3 similar experiments. (D) Mononuclear cell lysates (300 µg) were 
immunoprecipitated with anti-Abl antibodies, and p87C3G detected with anti-C3G (c-
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19) antibodies. H, healthy individual; >90%, CML patient at the time of diagnosis; 50%, 
CML patient containing about 50% Ph+ cells; 0%, CML patient with complete 
cytogenetic response; b, beads incubated with cell lysate from a 90% Ph+ patient.  
 
Figure 5. p87C3G interacts with Bcr-Abl through its SH3-b domain. (A) Total 
cell lysates of K562 were pulled down with C3G12, CAT, SH3-b, p87 and P2 GST-
fusion proteins bound to glutathione-sepharose beads, and analyzed by immunoblotting 
with antibodies to Abl (upper panel) and CrkL (middle panel). (B) K562 cell lysates 
were pulled down with GST alone or fused to the SH3 domain of Abl and analyzed by 
immunoblotting with antibodies to C3G (c-19) (upper panel) and CrkL (middle panel). 
(C) Pull down analysis with anti-Abl (upper panel) or anti-CrkL (middle panel) 
antibodies of K562 lysates incubated with wild type GST-p87 fusion protein (p87) or 
versions of GST-p87 mutated in the P2 (p87-mP2), P3 (p87-mP3) or P4 (p87-mP4) 
polyproline stretches. (A-C) Bottom panels: Coomassie stained gels of corresponding 
GST-fusion proteins. In all cases, equal volumes of purified protein, obtained from the 
same amount of bacteria, were loaded. b, beads incubated with cell lysate; L, cell lysate. 
All panels are representative of 3 independent experiments. 
 
Figure 6. p87C3G is tyrosine phosphorylated by two different mechanisms. (A) 
p87C3G and CrkL are constitutively phosphorylated in Boff 210 and K562 cells. Cell 
lysates, treated as indicated, were immunoprecipitated with anti-p-Tyr antibodies and 
immunoblotted with antibodies to C3G (c-19) or CrkL. Lower panels show similar 
amount of p87C3G in all samples. St, starved cells; Dx, doxycycline; C, serum-growing 
cells. (B) K562 cells were  immunoprecipitated with anti-C3G (c-19) antibodies and 
subjected to in vitro kinase reactions with [γ32P]ATP. (C) K562 cells untreated or 
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treated with STI571 were immunoprecipitated with anti-Abl antibodies and subjected to 
in vitro kinase reactions with [γ32P]ATP. 32P-phosphorylated proteins were detected by 
autoradiography. b, beads incubated with cell lysate. (D) Upper panel, lysates of K562 
cells treated or not with STI571 were immunoprecipitated with anti-Abl, anti-C3G (c-
19) and anti-Hck (N-30) antibodies as indicated and subjected to in vitro kinase assay 
by incubation with cold ATP. Phosphorylated proteins were detected by Western blot 
with anti p-Tyr antibodies; lower panel, same blot stripped and incubated with anti-C3G 
(c-19) and anti-Hck polyclonal (two left lanes) or monoclonal (rest of lanes) antibodies. 
The blots are representative of 5 experiments. 
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